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A B S T R A C T
Purpose
The Letrozole (Femara) Versus Anastrozole Clinical Evaluation (FACE) study compared the efﬁcacy
and safety of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone
receptor (HR) –positive and node-positive early breast cancer (eBC).
Methods
Postmenopausal women with HR-positive and node-positive eBC were randomly assigned to re-
ceive adjuvant therapy with either letrozole (2.5 mg) or anastrozole (1 mg) once per day for 5 years or
until recurrence of disease. Patients were stratiﬁed on the basis of the number of lymph nodes and
human epidermal growth factor receptor 2 status. The primary end point was 5-year disease-free
survival (DFS), and the key secondary end points were overall survival and safety.
Results
A total of 4,136 patients were randomly assigned to receive either letrozole (n = 2,061) or anastrozole
(n = 2,075). The ﬁnal analysis was done at 709 DFS events (letrozole, 341 [16.5%]; anastrozole, 368
[17.7%]). The 5-year estimated DFS rate was 84.9% for letrozole versus 82.9% for anastrozole arm
(hazard ratio, 0.93; 95%CI, 0.80 to 1.07;P= .3150). Exploratory analysis showed similar DFSwith letrozole
and anastrozole in all evaluated subgroups. The 5-year estimated overall survival rate was 89.9% for
letrozole versus 89.2% for anastrozole arm (hazard ratio, 0.98; 95% CI, 0.82 to 1.17; P = .7916). Most
common grade 3 to 4 adverse events (. 5% of patients) reported for letrozole versus anastrozole were
arthralgia (3.9% v 3.3%, and 48.2% v 47.9% for all adverse events), hypertension (1.2% v 1.0%), hot
ﬂushes (0.8% v 0.4%), myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depression (0.8% v 0.6%).
Conclusion
Letrozole did not demonstrate signiﬁcantly superior efﬁcacy or safety compared with anastrozole in
postmenopausal patients with HR-positive, node-positive eBC.
J Clin Oncol 35:1041-1048. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Breast cancer (BC) is the most common cancer
affecting women worldwide,1 with an estimated
1.67 million new cancer cases diagnosed in 2012.2
Almost 80% of all BCs are hormone receptor
(HR) positive (estrogen receptor positive and/or
progesterone receptor positive).3 Aromatase in-
hibitors (AIs) such as anastrazole, letrozole, and
exemestane are the current standard of care as
adjuvant therapy for postmenopausal women
with estrogen receptor–positive early breast
cancer (eBC).4,5
Both letrozole and anastrozole have been
shown to have superior efﬁcacy compared with
tamoxifen.6,7 In the Breast International Group
(BIG) 1-98 trial (median follow-up, 8.7 years),
letrozole monotherapy was signiﬁcantly more ef-
fective than tamoxifen, whether by inverse prob-
ability of censoring weighting or intention-to-treat
analysis (inverse probability of censoring weighting
disease-free survival [DFS] hazard ratio, 0.82; 95%
CI, 0.74 to 0.92; intention-to-treat DFS hazard
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ratio, 0.86; 95% CI, 0.7 to 0.96).6 The Arimidex, Tamoxifen, Alone
or in Combination (ATAC) trial demonstrated that anastrozole
signiﬁcantly prolonged DFS (hazard ratio, 0.91; 95% CI, 0.83 to
0.99; P = .04) and time to recurrence (hazard ratio, 0.84; 95% CI,
0.75 to 0.93; P = .001) and signiﬁcantly reduced distant metastases
(hazard ratio, 0.87; 95%CI, 0.77 to 0.99; P= .03) versus tamoxifen as
adjuvant endocrine therapy in postmenopausal women with HR-
positive BC.7 Pharmacodynamic studies have shown that letrozole
more effectively suppresses plasma estradiol levels than anastrozole in
patients with advanced BC,8 but the unanswered question is whether
this translates into better efﬁcacy. There were no head-to-head trials
comparing the two treatments in the adjuvant setting until now.
Published data have indicated that the relative beneﬁt of both
agents varies across patient subgroups,9,10 and, in particular, an
exploratory analysis of the BIG 1-98 trial showed that patients with
node-positive disease seemed to derive a greater beneﬁt versus
tamoxifen than did patients with node-negative disease.9 Hence, it
was believed that there was an unmet need, ﬁrst, to assess head to
head the relative efﬁcacy of these two nonsteroidal aromatase
inhibitors and, second, to evaluate their beneﬁt in higher-risk
patients with node-positive disease. The phase III randomized,
open-label, multicenter Femara Versus Anastrozole Clinical
Evaluation (FACE) trial (NCT00248170) was therefore designed to
compare the efﬁcacy and safety of adjuvant letrozole versus




The patient population included postmenopausal women with HR-
positive and node-positive eBC (stage IIA to IIIC invasive cancer) who were
within 12weeks after breast surgery or completion of adjuvant chemotherapy.
Patients who received neoadjuvant chemotherapy or adjuvant treatment with
trastuzumabwere also eligible. All patients had aWHOperformance status of
0 or 1. Patients with metastatic or inﬂammatory BC (as documented by
dermal lymphatic invasion), contralateral BC, or metachronous bilateral BC,
including ductal carcinoma in situ, were excluded. Patients who had received
neoadjuvant endocrine therapy or adjuvant antiestrogen therapy for
. 1 month after surgery, radiotherapy, and/or chemotherapy and patients
with Child-Pugh grade C cirrhosis were not eligible for the trial.
Study Design
In this phase IIIb, open-label, multicenter trial conducted across 271
international centers, patients were randomly assigned 1:1 to receive either
adjuvant letrozole (2.5 mg) or anastrozole (1 mg) once per day until disease
recurrence/relapse or for a maximum of 5 years. There was no pre-
determined per-patient follow-up period. Two interim analyses were
planned for DFS, after approximately one third (320 events) and two thirds
(639 events) of the total number of events (959 events). Disease recurrence
was assessed as per local practice guidelines by x-ray, computed tomog-
raphy, ultrasound, or magnetic resonance imaging.
Patients were stratiﬁed on the basis of the number of lymph nodes
(one to three or four or more) and human epidermal growth factor re-
ceptor 2 (HER2) status by locally assessed ﬂuorescence in situ hybrid-
ization or immunohistochemistry.
End Points and Analysis Sets
The primary end point was DFS, deﬁned as date from randomization
to recurrence of invasive BC (local, regional, or distant), new invasive
cancer in the contralateral breast, or death from any cause. The secondary
end points were overall survival (OS; time from randomization to death
from any cause), time to development of distant metastases (TDM), distant
disease-free survival (DDFS), and safety. TDM was deﬁned as the time
from the date of randomization to the date of ﬁrst development of any
recurrent or metastatic disease in sites other than the local mastectomy scar,
the ipsilateral breast in case of breast conservation, or the contralateral
breast. DDFS was the time from the date of randomization to the date of the
ﬁrst development of any recurrence at a distant site or death from any cause.
The intent-to-treat (ITT) population consisted of all randomly
assigned patients. The safety cohort included all the patients from the ITT
population who received study therapy and had at least one safety as-
sessment after the baseline assessment. The primary efﬁcacy evaluation was
based on the ITT set and the safety evaluation on the safety set.
Statistical Analysis
A stratiﬁed two-sided log-rank test was used to test the treatment
difference in terms of DFS, stratifying for number of lymph nodes (one to
three or four or more) and HER2 status (positive or negative). The sample
size calculation was based on an expected 5-year DFS of 76.5% for
anastrozole versus 80.0% for letrozole, corresponding to a hazard ratio of
0.83 favoring letrozole. These calculations took two interim analyses into
account, with adjustment to the signiﬁcance levels performed via an
O’Brien Fleming design. Accounting for 5% loss to follow-up, with 4,000
patients, 2,000 in each arm leading to 959 events would give the study 80%
power (two-sided 0.05 signiﬁcance level) to detect a DFS difference of 3.5%
between the treatment arms. On the basis of the observed event rate and
also on the availability of patients who could be reconsented for longer
follow-up, it was estimated that it could take until 2022 to reach the
required 959 events. Hence, after discussion with the steering committee
and with notiﬁcation of the Independent Data Monitoring Committee, the
study was terminated early (September 8, 2014). At the time of ﬁnal
analysis, 709 DFS events were included. P value was obtained from the two-
sided stratiﬁed log-rank test. The hazard ratio and associated 95% CIs were
obtained using a stratiﬁed Cox model by number of lymph nodes (one to
three or four or more) and HER2 status. A sensitivity analysis using a Cox
proportional hazards model adjusting for the number of lymph nodes and
HER2 status has also been performed. The hazard ratio and associated 95%
CI for subgroup analyses were obtained using an unstratiﬁed Cox model.
Ethics and Role of Sponsor
The study protocol and informed Consent Formwere reviewed by the
independent ethics committee or institutional review board for each
center, and the study participants were provided with institutional review
board/independent ethics committee–approved written informed consent.
Patients who did not provide informed consent before randomization were
removed from the intent-to-treat (ITT) population and were captured as
protocol deviations. The study was conducted in accordance with the
ethical principles of the Declaration of Helsinki and Good Clinical Practice
Guidelines.
The study was sponsored by Novartis Pharmaceuticals and overseen
by an independent data monitoring committee with guidance from the
study steering committee. The data analysis was performed by an in-
dependent statistical group (Michelangelo), and the study sponsor
remained blinded until the analysis was complete. The investigators
performed the trial-related activities on the basis of the contractual terms
of the trial and retained their independence from the sponsor.
RESULTS
Baseline Characteristics
A total of 4,172 patients were randomly assigned between
December 2005 and March 2008. Two patients were randomly
1042 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Smith et al
Downloaded from ascopubs.org by INSTITUTE CANCER RESEARCH on April 28, 2017 from 193.063.219.242
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
assigned in error before they had signed the informed consent, and
34 patients had baseline assessments performed before signing the
informed consent. After the exclusion of these 36 patients from the
ITT and safety populations, a total of 4,136 patients received either
letrozole (n = 2,061) or anastrozole (n = 2,075; Data Supplement).
Treatment arms were well balanced with respect to baseline char-
acteristics (Table 1). The median age in both treatment arms was
62 years, and the majority of patients (approximately 86%) were
white. The main prior antineoplastic therapies patients had received
in the letrozole versus anastrozole arms included adjuvant che-
motherapy (62.7% v 61.1%) and radiotherapy (31.6% v 29.9%).
Patient Disposition
Among the total 4,136 patients, 12 from the letrozole arm
and 13 from the anastrozole arm were untreated. The safety
population included a total of 4,111 patients who actually took
treatment in the letrozole (n = 2,049) and anastrozole arms
(n = 2,062; Appendix Table A1, online only). The median
duration of exposure was approximately 60 months in both the
arms at the ﬁnal analysis in February 2015. The median duration
of follow-up was 65 months in all study patients. Treatment
discontinuation was reported in 36.1% and 38.1% of the pa-
tients in the letrozole arm and anastrozole arms, respectively.
Primary reasons for discontinuation in both the letrozole and
anastrozole arms were adverse events (AEs; 15.1% v 14.3%) and
disease progression (9.5% v 10.4%). Patients who were lost to
follow-up comprised 1.4% and 1.7% in letrozole and anas-
trozole arms, respectively.
Efﬁcacy. DFS. No statistically signiﬁcant difference in DFS
was observed between the treatment arms (hazard ratio, 0.93; 95%
CI, 0.80 to 1.07; stratiﬁed log-rank test, P = .3150; Fig 1). At the
ﬁnal analysis with 709 DFS events, the 5-year estimated DFS rate
was 84.9% (95% CI, 83.2% to 86.4%) for letrozole versus 82.9%
(95% CI, 81.2% to 84.5%) for anastrozole, respectively. The
median DFS was not reached in either of the treatment arms.
Similar 5-year DFS estimates were observed for letrozole versus
anastrozole in all evaluated exploratory subgroups, including body
mass index, prior adjuvant chemotherapy, tumor stage, HER2
status, and geographic region (Fig 2).
OS. No statistically signiﬁcant difference in OS was observed
between the treatment arms, with a hazard ratio of 0.98 (95%CI, 0.82
to 1.17; P = .7916). At the ﬁnal analysis, 235 (11.4%) deaths were
recorded in the letrozole arm versus 242 (11.7%) deaths in the
anastrozole arm. The median OS was not reached in either of the
treatment arms. The 5-year estimatedOS for letrozole and anastrozole
arms was 89.9% (95% CI, 88.5% to 91.1%) and 89.2% (95% CI,
87.8% to 90.5%), respectively (Fig 3).
TDM and DDFS. The percentage of patients who developed
distant metastases was 10.8% in each arm. Time to distant me-
tastases (TDM) was comparable between the two treatment arms
(hazard ratio, 0.99; 95% CI, 0.82 to 1.19; P = .9391), and the
median TDM was not reached in either arm (Appendix Fig A1,
online only). Similarly, the percentage of patients who developed
distant disease-free survival (DDFS) was 15.7% and 16.2% in the
letrozole and anastrozole arms, respectively. DDFSwas comparable
between the treatment arms (hazard ratio, 0.96; 95% CI, 0.82 to
1.12; P = .6204), and the median DDFS was not reached in either
arm (Appendix Fig A2, online only). Distant recurrence occurred
in 11% of both the treatment arms, and the sites of metastases were
also similar in the two arms. Secondary malignancies occurred in
4.1% and 4.8% of the letrozole- and anastrozole-treated patients,
respectively.
Safety. The safety proﬁles of the two treatment arms were
similar (Table 2). The most common AEs (. 10% of patients)
reported were arthralgia (48.2% v 47.9%), hot ﬂushes (32.5% v
32.3%), fatigue (16.8% v 16.6%), osteoporosis (10.9% v 10.9%),
myalgia (11.4% v 10.3%), and back pain (10.3% v 9.4%). The most
common grade 3 or 4 AEs (. 0.8% of patients) reported for






Age, median (range), years 62 (33-96) 62 (33-92)
Age category, years
, 65 1,236 (60.0) 1,254 (60.4)
$ 65 825 (40.0) 821 (39.6)
Race, n (%)
White 1,775 (86.1) 1,799 (86.7)
Black 26 (1.3) 32 (1.5)
Asian 204 (9.9) 196 (9.4)
Native American 3 (0.1) 5 (0.2)
Paciﬁc islander 3 (0.1) 2 (0.1)
Other 50 (2.4) 41 (2.0)
Performance status (WHO)
0 1,634 (79.3) 1,666 (80.3)
1 404 (19.6) 394 (19.0)
2 2 (0.1) 2 (0.1)
Missing 21 (1.0) 13 (0.6)
Postmenopausal status
Age $ 50 years and amenorrheic
for $ 6 months in the absence
of chemotherapy
1,912 (92.8) 1,920 (92.5)
Age , 50 years and amenorrheic
for $ 12 months in the absence
of chemotherapy
37 (1.8) 39 (1.9)
Prior bilateral oophorectomy 94 (4.6) 100 (4.8)
Missing 18 (0.9) 16 (0.8)
ER status
Negative 32 (1.6) 22 (1.1)
Positive 2,028 (98.4) 2,053 (98.9)
Unknown 1 (0.0) 0
Progesterone receptor status
Negative 387 (18.8) 405 (19.5)
Positive 1,645 (79.8) 1,648 (79.4)
Unknown 29 (1.4) 22 (1.1)
HER2 status
Negative 1,825 (88.5) 1,835 (88.4)
Positive 235 (11.4) 239 (11.5)
Unknown 1 (, 0.1) 1 (, 0.1)
No. of lymph nodes
1-3 1,477 (71.7) 1,477 (71.2)
$ 4 584 (28.3) 598 (28.8)
Tumor stage*
T0 or T1 968 (47.0) 945 (45.5)
T2 908 (44.1) 926 (44.6)
$ 3 177 (8.6) 196 (9.4)
Prior antineoplastic therapy
Radiotherapy 652 (31.6) 621 (29.9)
Adjuvant chemotherapy 1,294 (62.7) 1,267 (61.1)
NOTE. Data presented as No. (%) unless otherwise noted.
Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor
receptor 2.
*Does not include patients with missing tumor stage (n = 1) or ductal carcinoma
in situ (n = 15).
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letrozole versus anastrozole, respectively, were arthralgia (3.9% v
3.3%), hypertension (1.2% v 1.0%), hot ﬂushes (0.8% v 0.4%),
myalgia (0.8% v 0.7%), dyspnea (0.8% v 0.5%), and depression
(0.8% v 0.6%; Table 3).
Grade 3 or 4 AEs, which were suspected to be treatment
related in the letrozole versus anastrozole arms, were 9.5% versus
8.1%, respectively. AEs that were suspected to be treatment re-
lated and led to letrozole versus anastrozole discontinuation
occurred in 14.0% versus 12.9% of patients, respectively. Serious
AEs, which were suspected to be drug related in the letrozole
versus anastrozole arms, occurred in 2.6% versus 2.3% of pa-
tients, respectively, and AEs leading to dose interruptions/
reductions occurred in 8.2% versus 7.7% of patients,
respectively. On-treatment deaths occurring in the letrozole-
versus anastrozole-treated patients were 42 (2.0%) versus 46
(2.2%; Table 2). The main causes of death during letrozole versus
anastrozole treatment were disease progression (147 [7.2%] v 142
[6.9%]), cardiac failure (6 [0.3%] v 2 [, 0.1%]), pulmonary
embolism (2 [0.1%] v 4 [0.2%]), and chronic obstructive pul-
monary disease (1 [0.05%] v 4 [0.2%]), respectively.
DISCUSSION
Anastrozole and letrozole have both been used as front-line ad-























0 12 24 36 48 60 72 84 96
2,061 1,984 1,885 1,795 1,704 1,441 264 8 1
2,075 1,995 1,887 1,791 1,685 1,404 259 7
Total Censored Events Kaplan-Meier medians 
Letrozole 2,061 1,720 341 NE 
Anastrozole 2,075 1,707 368 NE 
Hazard ratio (95% CI): 0.93 (0.80 to 1.07)
Log-rank P value (letrozole v anastrozole): .3150 




BMI, kg/m2 Normal (< 29) 2,645
Overweight (29 to < 35) 934
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84.9 (83.2 to 86.4)
85.1 (83.0 to 86.9)
83.6 (79.9 to 86.7)
86.1 (80.2 to 90.3)
82.8 (79.9 to 85.4)
86.1 (84.0 to 87.9)
89.7 (87.5 to 91.5)
81.3 (78.5 to 83.8)
76.7 (69.7 to 82.4)
86.5 (81.3 to 90.3)
84.7 (82.9 to 86.3)
88.7 (86.9 to 90.2)
75.1 (71.3 to 78.5)
85.2 (79.2 to 89.6)
84.9 (82.8 to 86.7)
84.7 (81.3 to 87.6)
Anastrozole
82.9 (81.2 to 84.5)
83.6 (81.4 to 85.5)
81.1 (77.1 to 84.5)
83.0 (77.4 to 87.3)
81.1 (78.2 to 83.7)
84.1 (81.9 to 86.0)
91.0 (88.9 to 92.7)
77.7 (74.8 to 80.3)
68.8 (61.7 to 74.8)
78.9 (73.0 to 83.6)
83.4 (81.6 to 85.1)
87.8 (86.0 to 89.4)
70.9 (67.0 to 74.4
81.2 (74.5 to 86.2)
83.4 (81.2 to 85.3)
82.3 (78.7 to 85.3)
Hazard Ratio (95% CI)†
0.93 (0.80 to 1.07)
0.93 (0.77 to 1.12)
0.95 (0.70 to 1.27)
0.86 (0.54 to 1.37)
0.96 (0.77 to 1.20)
0.90 (0.74 to 1.10)
1.23 (0.93 to 1.62)
0.86 (0.70 to 1.04)
0.77 (0.53 to 1.12)
0.69 (0.45 to 1.06)
0.96 (0.82 to 1.13)
1.00 (0.82 to 1.23)
0.86 (0.69 to 1.06)
0.73 (0.44 to 1.20)
0.96 (0.80 to 1.15)
0.91 (0.68 to 1.22)
0.4 0.6
Letrozole better Anastrozole better
0.8 1 1.2 1.4 1.6
DFS (95% CI), %
Fig 2. Exploratory subgroup analyses of 5-year disease-free survival (DFS) by baseline characteristics. BMI, body mass index; DFS, disease-free survival; HER2, human
epidermal growth factor receptor 2. (*)Sum of N in subgroups is not always 4,136 because ofmissing data. (†)The hazard ratio was obtained from an unstratiﬁed Coxmodel
except for All, which was obtained from the stratiﬁed Cox model by number of lymph nodes and HER2 status.
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more than a decade, and yet there have been no clinical ran-
domized data on their relative efﬁcacies until now. Circum-
stantial evidence suggested that letrozole might be superior. For
example, the BIG 1-98 trial analysis at a median of 8.3 years of
follow-up after censoring patients for crossover showed a sig-
niﬁcant OS beneﬁt with letrozole compared with tamoxifen
(hazard ratio, 0.82; P, .05).11 In contrast, in the ATAC trial, no
survival beneﬁt with anastrozole compared with tamoxifen was
noted even after 10 years of follow-up (hazard ratio, 0.97;
P = .7).12 Likewise, letrozole has been shown to be a more potent
inhibitor of aromatization and suppressant of circulating levels of
serum estrone and estrone sulfate than anastrozole in small
studies.13,14
Against this background, the present FACE trial involving
more than 4,000 patients with node-positive disease failed to
conﬁrm the hypothesis that letrozole might be clinically
superior to anastrozole as adjuvant endocrine therapy in
postmenopausal women. These ﬁndings are comparable with
results from the phase III trial, NCIC Clinical Trials Group
MA.27, which likewise failed to show superior outcomes
after 5 years of adjuvant therapy with exemestane versus
anastrozole; estimated 4-year DFS rate was 91.0% for
exemestane versus 91.2% for anastrozole.15 They are also in
line with the American College of Surgeons Oncology Group
(ACOSOG) Z1031, randomized, phase II, neoadjuvant trial,
in which no signiﬁcance difference in clinical responses
was observed between letrozole, anastrozole, and exemes-
tane.16 The observations from the FACE study are also in
line with results from an early trial comparing letrozole and
anastrozole as second-line treatment of advanced BC in 713
patients; no difference was observed in either time to pro-
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2,061 1,995 1,926 1,861 1,785 1,638 382 11 1




Total Censored Events Kaplan-Meier medians 
Letrozole 2,061 1,826 235 NE 
Anastrozole 2,075 1,833 242 NE 
Hazard ratio (95% CI): 0.98 (0.82 to1.17)
Log-rank P value (letrozole v anastrozole): .7916 
Fig 3. Overall survival. NE, non-evaluable.
Table 2. Safety Summary
Event Letrozole (n = 2,049) Anastrozole (n = 2,062)
All deaths 235 (11.5) 240 (11.6)
On-treatment deaths* 42 (2.0) 46 (2.2)
Any grade AEs, all/suspected to be drug related 2,049 (100)/1,558 (76.0) 2,062 (100)/1,570 (76.1)
Grade 3 or 4 AEs, all/suspected to be drug related 628 (30.6)/194 (9.5) 591 (28.7)/168 (8.1)
Clinically notable AEs, all/suspected to be drug related 305 (14.9)/50 (2.4) 244 (11.8)/40 (1.9)
Clinical fractures 191 (9.3) 166 (8.0)
Ischemic heart disease 49 (2.4) 31(1.5)
Thromboembolic events 25 (1.2) 24 (1.2)
Cardiac failures/disorders† 31 (1.5) 15 (0.7)
Cerebrovascular accidents 33 (1.6) 30 (1.5)
Serious AEs, all/suspected to
be drug related‡
486 (23.7)/54 (2.6) 520 (25.2)/48 (2.3)
AEs leading to discontinuation 357 (17.4) 337 (16.3)
Suspected to be drug related 286 (14.0) 265 (12.9)
Other signiﬁcant AEs 1,495 (73.0) 1,526 (74.0)
AEs requiring dose interruption/reduction 167 (8.2) 158 (7.7)
AEs requiring additional therapy 1,470 (71.1) 1,493 (72.4)
NOTE. Data presented as No. (%).
Abbreviation: AE, adverse event.
*Themain causes of on-treatment deaths (up to 28 days after end of treatment) were breast cancer (0.5% v 0.3%), cardiac failure (0.2% v 0.0%), and chronic obstructive
pulmonary disease (0.0% v 0.1%).
†Cardiac failures/disorders include cardiac failure, cardiac failure congestive, cardiac failure acute, cor pulmonale, and diastolic dysfunction.
‡Serious adverse events were indicated as such by the investigators and reported to the sponsor’s drug safety department.
jco.org © 2017 by American Society of Clinical Oncology 1045
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to anastrozole regarding overall response rate (19.1% v 12.3%;
P = .013).
An important secondary ﬁnding of the FACE trial was the lack of
relationship between obesity and outcome. It has been argued that
aromatase inhibitors may be less effective in depleting estradiol in
obese women, because of the greater quantity of aromatase in pe-
ripheral fatty tissue.18,19 In the ATAC trial, anastrazole seemed less
effective in postmenopausal women who were obese, possibly
reﬂecting its incomplete suppression of estrogen.20,21 In contrast, in
the BIG 1-98 trial, letrozole beneﬁt over tamoxifen did not seem to be
inﬂuenced by the patient’s bodymass index,22 with the hypothesis that
this reﬂected its more complete estrogen suppression. In the FACE
trial, however, no signiﬁcant advantage was seen for letrozole over
anastrozole even in patients deﬁned as obese or morbidly obese in an
exploratory analysis, despite a nonsigniﬁcant trend in favor of
letrozole in obese patients, but with wide CIs (hazard ratio, 0.86; 95%
CI, 0.54 to 1.37; Fig 2). Our results therefore do not support the
hypothesis that obese patients may do better on letrozole than
anastrozole.
When the FACE trial was designed, treatment was planned
for 5 years or until disease progression, but no set duration of
follow-up was determined. Follow-up in the FACE trial was
stopped in 2014 by the sponsors because of the lower-than-
expected event rate, funding issues, and challenges in restarting
and reconsenting patients globally to allow for further follow-
up. Nevertheless, the 5-year follow-up results of both the ATAC
and the BIG 1-98 trials correctly predicted longer-term out-
comes, with the exception that the OS beneﬁt in BIG 1-98 only
emerged several years later. The close similarity in the outcome
results after 5 years in the FACE trial argues strongly against the
likelihood of a clinically signiﬁcant beneﬁt for either agent
emerging later.
A possible small caveat to this was a subgroup analysis
showing a nonsigniﬁcant trend in favor of letrozole for high-risk
patients with four or more nodes involved (hazard ratio for DFS,
0.86; 95% CI, 0.69 to 1.06; Fig 2). A similar trend was reported in
the BIG 1-98 trial, in which patients at highest risk had the
greatest efﬁcacy advantage of letrozole over tamoxifen.9 The
safety proﬁles of letrozole and anastrozole in FACE were com-
parable, and AE-related treatment discontinuations were re-
ported in 15.1% and 14.3% of patients in the letrozole and
anastrozole arms, respectively. In contrast, in the NCIC Clinical
Trials Group MA.27 trial, the AE-related discontinuation rate for
exemestane was slightly higher (33.8%) than for anastrozole
(29.4%).15 In a smaller comparative trial of letrozole and anas-
trozole in patients with metastatic BC, the rates of AEs, serious
AEs, and treatment discontinuations were similar, and no sig-
niﬁcant safety differences were observed between the two
treatment arms.17
There is an increasing interest in extending adjuvant endo-
crine therapy beyond 5 years, in so-called extended adjuvant
therapy. In the MA.17R trial, which involved 1,918 women,
extending the treatment with letrozole to 10 years resulted in
signiﬁcantly improved DFS. The 5-year DFS was 95% (95% CI,
93% to 96%) in the letrozole group and 91% (95% CI, 89% to
93%) in the placebo group, (hazard ratio, 0.66; 95% CI, 0.48 to
0.91; P = .01).23 It is possible that the lower-than-anticipated event
rate (709 v 959 planned DFS events), which led to premature
termination of the FACE trial, may have been inﬂuenced to some
extent by the use of extended adjuvant endocrine therapy in some
patients, despite this not being prescribed in the protocol. How-
ever, data to support or refute this are not available.
In conclusion, Letrozole did not provide statistically su-
perior efﬁcacy over anastrozole in either the primary end point
Table 3. Most Common Adverse Events (. 5% of patients)
Preferred Term
Letrozole (n = 2,049) Anastrozole (n = 2,062)
Grade 3 or 4 All Grades Grade 3 or 4 All Grades
Arthralgia 80 (3.9) 987 (48.2) 69 (3.3) 987 (47.9)
Hot ﬂush 17 (0.8) 666 (32.5) 9 (0.4) 666 (32.3)
Fatigue 8 (0.4) 345 (16.8) 10 (0.5) 343 (16.6)
Osteoporosis 5 (0.2) 223 (10.9) 11 (0.5) 225 (10.9)
Myalgia 16 (0.8) 233 (11.4) 15 (0.7) 212 (10.3)
Back pain 11 (0.5) 212 (10.3) 17 (0.8) 193 (9.4)
Osteopenia 4 (0.2) 203 (9.9) 1 (0.0) 173 (8.4)
Pain in extremity 9 (0.4) 168 (8.2) 3 (0.1) 174 (8.4)
Lymphedema 5 (0.2) 159 (7.8) 2 (0.1) 179 (8.7)
Insomnia 7 (0.3) 160 (7.8) 3 (0.1) 149 (7.2)
Hypercholesterolemia 2 (0.1) 155 (7.6) 1 (0.0) 151 (7.3)
Hypertension 25 (1.2) 156 (7.6) 20 (1.0) 149 (7.2)
Depression 16 (0.8) 147 (7.2) 13 (0.6) 137 (6.6)
Bone pain 10 (0.5) 138 (6.7) 9 (0.4) 122 (5.9)
Nausea 6 (0.3) 137 (6.7) 5 (0.2) 152 (7.4)
Headache 3 (0.1) 130 (6.3) 5 (0.2) 168 (8.1)
Alopecia 2 (0.1) 127 (6.2) 0 (0.0) 134 (6.5)
Musculoskeletal pain 6 (0.3) 123 (6.0) 9 (0.4) 147 (7.1)
Radiation skin injury 11 (0.5) 120 (5.9) 6 (0.3) 88 (4.3)
Dyspnea 16 (0.8) 118 (5.8) 10 (0.5) 96 (4.7)
Cough 1 (0.0) 106 (5.2) 1 (0.0) 120 (5.8)
Musculoskeletal stiffness 2 (0.1) 102 (5.0) 2 (0.1) 84 (4.1)
Dizziness 2 (0.1) 94 (4.6) 7 (0.3) 109 (5.3)
NOTE. Data presented as No. (%).
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of DFS or the secondary end point of OS. No new safety concerns
were identiﬁed, and there were no unexpected short-term or long-
term treatment-related toxicities in either of the treatment arms.
The study was terminated prematurely because of lower-than-
expected DFS events, and the data presented here are based on the
ﬁnal analysis of 709 DFS events. Primary BC tissue, blood, and
germline single nucleotide polymorphism biomarker analyses are
currently ongoing.
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Untreated 12 (0.6) 13 (0.6)
Treated 2,049 (99.4) 2,062 (99.4)




1,315 (63.8) 1,285 (61.9)
Adverse event(s) 311 (15.1) 296 (14.3)
Disease progression 196 (9.5) 216 (10.4)
Abnormal test procedure result(s) 49 (2.4) 61 (2.9)
Subject withdrew consent 71 (3.4) 79 (3.8)
Protocol violation 35 (1.7) 30 (1.4)
Death 28 (1.4) 47 (2.3)
Lost to follow-up 28 (1.4) 35 (1.7)
Administrative problems 22 (1.1) 25 (1.2)
Abnormal laboratory value(s) 4 (0.2) 0





























0 12 24 36 48 60 72 84 96
2,061 1,986 1,894 1,799 1,717 1,450 265 8 1
2,075 1,987 1,885 1,802 1,709 1,421 262 7
Total Censored Events Kaplan-Meier medians 
Hazard ratio (95% CI): 0.99 (0.82 to 1.19)
Log-rank P value (letrozole v anastrozole): .9391 
Letrozole 2,061 1,838 223 NE 
Anastrozole 2,075 1,850 225 NE 
Fig A1. Time to distant metastases. NE, not evaluable.
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0 12 24 36 48 60 72 84 96
No. at risk
Anastrozole
Letrozole 2,061 1,990 1,898 1,808 1,720 1,450 266 8 1
2,075 1,998 1,900 1,807 1,707 1,424 262 7
Total Censored Events Kaplan-Meier medians 
Letrozole 2,061 1,738 323 NE 
Anastrozole 2,075 1,738 337 NE 
Hazard ratio (95% CI): 0.96 (0.82 to 1.12)
Log-rank P value (letrozole v anastrozole): .6204 
Fig A2. Distant disease-free survival. NE, non-evaluable.
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